Endeavour Vision
VC Fund
Geneva, Switzerland
Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive internationalexperience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017). Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.
- Total investments:
- 76
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $375M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Endeavour Vision invests in
Stages Endeavour Vision invests in
Countries Endeavour Vision invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Series A
- $2.1M–$30M
- Series B
- $7M–$48M
- Series C
- $12M–$115M
Investment Focus
Industry
- Health Care 27 (36%)
- Medical 18 (24%)
- Biotechnology 17 (22%)
- Medical Device 15 (20%)
- Software 6 (8%)
Stage
- Series C 15 (20%)
- Series B 12 (16%)
- Series A 9 (12%)
- Series D 7 (9%)
- Funding Round 6 (8%)
Country
- United States 24 (32%)
- Switzerland 6 (8%)
- France 2 (3%)
- Germany 2 (3%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alex Schmitz
Partner
|
Partner | Total investments: 16 | Find email | |
Bernard Vogel
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 10 | Find email | |
Damien Tappy
President & Managing Partner
|
President & Managing Partner | Total investments: 6 | Find email | |
Daniel van den Bergh
Senior Investment Director
|
Senior Investment Director | Total investments: 3 | Find email | |
Fernando Pacheco
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kestra Medical Technologies, Inc.
|
Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients. | $196M / Private Equity / Jul 24, 2024 | |
Nalu Medical
|
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $85M / Series E / Jan 03, 2024 | |
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $42.5M / Oct 25, 2023 | |
|
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $42.5M / Oct 25, 2023 | |
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $30M / Series C / Sep 19, 2023 | |
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $50M / Series G / Mar 27, 2023 | |
Venture Med Group
|
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device. | Convertible Note / Jan 31, 2023 | |
Miach Orthopaedics
|
Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury.Miach Orthopaedicswas founded on 2016 and is headquartered in Westborough, Massachusetts. | $30M / Series B / Jan 25, 2023 | |
HealthJoy
|
HealthJoy is a benefits experience platform helping companies save money while improving employee satisfaction. Through personalized guidance and AI technology, it empowers employees to better use and understand their benefits. The result is happier employees, increased cost containment, and fewer questions for HR.HealthJoy integrates a client’sexisting benefits to deliver each employee a personalized digital benefits wallet that keeps benefits top-of-mind. Employees also gain on-demand access to online medical consultations, live healthcare concierges, Rx savings, and much more. HealthJoy empowers employees to become educated healthcare shoppers and fundamentally changes healthcare dynamics. | $60M / Series D / Oct 27, 2022 | |
IntelyCare
|
IntelyCare offers a digital workforce augmentation platform that combines a gig-model application with advanced data science to optimize staff resources and close the widening gap between workforce supply and demand. IntelyCare is revolutionizing the antiquated healthcare staffing market, filling nursing shifts at three times the industry averageand giving post-acute facilities the tools to predict and manage staffing needs. The company’s engaging mobile app empowers nursing professionals with access to flexible, on-demand work opportunities, reducing burnout and attrition while increasing productivity. | $115M / Series C / Apr 06, 2022 | |
| See all 76 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Endeavour Vision invest in?
Endeavour Vision invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series B stage. Most of the 76 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Endeavour Vision's check size?
Endeavour Vision typically joins rounds of $2.1M–$30M at Series A, $7M–$48M at Series B and $12M–$115M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Endeavour Vision participates in.
How do I contact Endeavour Vision?
Public channels for Endeavour Vision include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Endeavour Vision?
The team at Endeavour Vision includes Alex Schmitz (Partner), Bernard Vogel (Founder and Managing Partner) and Damien Tappy (President & Managing Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
